Table 4.

Response outcomes for parts A and B

	NE	NR	PR	CR	Overall response (PR + CR), n (%)
Part A (n = 12)	1*	4†	3‡	4	7 (58)
Part B (n = 4)†		2	1	1	2 (50)
Part A + B ORR					9 (75)
95% CI, %					42.8-94.5

NE, not evaluable; NR, no response.

^*NE due to patient decision to withdraw from study after 4 cycles because of gastrointestinal toxicity.

^†Four patients from part A who had NR entered part B combination idasanutlin + IFN-α.

^‡Residual splenomegaly likely resulting from known portal vein thrombosis in 1 patient, likely a CR (n = 1).